How to Commercialize University Research

Mike Hull • September 14, 2026

University research can create enormous scientific value without ever becoming a product. Commercialization requires a second layer of work: translating the discovery into a defined use case, protectable asset, development plan, evidence package, and funding strategy that a customer, licensee, investor, or strategic partner can act on.

1. Start with the Problem, Not the Technology

Academic discoveries are often described by mechanism, platform, assay, material, or technical novelty. Commercialization begins by identifying the problem the discovery could solve, who experiences that problem, and why the current alternatives are inadequate.



A single technology may have many possible applications. The first commercialization task is to choose a beachhead opportunity where the unmet need, technical fit, evidence requirements, and market pathway are attractive enough to justify focused development.


  • Who has the problem?
  • How is it solved today?
  • What is meaningfully better about the new approach?
  • What evidence would persuade a user, buyer, licensee, or investor?

2. Protect the Intellectual Property before Public Disclosure

For university-originated inventions, the technology-transfer office should be involved early. Publication, presentations, posters, grant disclosures, and conference activity can affect patent strategy. Researchers should understand invention disclosure requirements, ownership, patent filing status, and any third-party obligations before beginning commercial outreach.

3. Decide What Commercialization Path Fits the Asset

Not every university technology needs a startup. Some assets are better suited for licensing to an established company; others may need a new company to perform the development work required before industry will engage. The decision should be driven by the asset, market, development burden, partner appetite, and the research team's goals.



  • License directly when an established company can absorb the technology with relatively little additional de-risking.
  • Form a startup when substantial development is required and a focused company can create value before licensing or acquisition.
  • Use sponsored research, option agreements, or strategic collaborations when more evidence is needed before a full commercial commitment.

4. Build a Commercialization Evidence Plan

The experiments needed for publication are not always the experiments needed for commercialization. Work backward from the next external decision-maker and ask what data would reduce the risk that person cares about. That may include comparative performance, manufacturability, clinical workflow, regulatory evidence, reimbursement, scalability, or customer validation.

5. Match Funding to the Next Milestone

University translational funds, SBIR/STTR, disease foundations, state programs, accelerators, strategic partners, and private capital can all play roles. The objective is to use the least expensive capital that can credibly reach the next value-creating milestone, especially before giving up significant equity.

6. Build the Commercial Team around Gaps

The academic inventor does not need to become the CEO. Successful commercialization often requires a combination of scientific leadership, product development, regulatory, market, business-development, and financing expertise. Identify the capabilities required for the next stage and fill them deliberately.

BYB Takeaway

The academic inventor does not need to become the CEO. Successful commercialization often requires a combination of scientific leadership, product development, regulatory, market, business-development, and financing expertise. Identify the capabilities required for the next stage and fill them deliberately.

Planning to commercialize university research? Use BYB resources to map the path before the most expensive decisions are made.

By Mike Hull September 13, 2026
It is the operating logic that explains how a scientific asset can move from its current state to a product that can be funded, licensed, approved, adopted, reimbursed, partnered, or sold.
By Mike Hull September 12, 2026
There is no universal amount of validation required before a biotech company raises capital. Investors fund risk, so a company does not need every question answered.
By Mike Hull September 11, 2026
For university inventors, one of the most important commercialization decisions is whether to license the technology directly to an established company or form a startup to develop it further.
By Mike Hull September 10, 2026
The Bootstrap Score™ is a practical framework for asking a more useful question: how much of the commercial risk has been reduced around the science?
By Mike Hull September 9, 2026
A paper can establish an important scientific finding, while a buyer, investor, regulator, licensee, or strategic partner may still see substantial unanswered risk.
By Mike Hull September 8, 2026
There is another risk that receives less attention—the Valley of Dilution™. It occurs when a company raises expensive equity before key uncertainties have been reduced.
By Mike Hull September 7, 2026
The Bootstrap Flywheel™ is a different model: use each small de-risking step to make the next step easier, cheaper, and more credible.
By Mike Hull September 6, 2026
The most important financing question for an early biotech company is often not how much money to raise. It is what type of money should fund the next milestone.
By Mike Hull September 5, 2026
Venture capital is not inherently too early or too expensive. It becomes expensive when founders use it to answer questions that could have been answered first with smaller or less dilutive resources.
By Mike Hull September 4, 2026
NIH Technical and Business Assistance—commonly called TABA—is designed to help SBIR and STTR recipients address product-development and commercialization needs that are often outside the core scientific aims of the award.